StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $12.15 | $12.08 | -0.58% | 0.1M |
| 05-13 | $11.95 | $11.18 | -6.44% | 0.1M |
| 05-14 | $11.21 | $11.04 | -1.52% | 0.1M |
| 05-15 | $11.03 | $10.55 | -4.35% | 0.0M |
| 05-18 | $10.25 | $10.56 | +3.02% | 0.1M |
AGMB files a foreign annual report (20-F) — limited XBRL coverage.
Foreign issuer. Files an annual 20-F with the SEC instead of 10-K/10-Q, and the XBRL tags often differ. We pull what we can; if a row reads 'Not available' the issuer didn't tag that line item.
Public market data, filings, and news are still available on this ticker via the other tabs.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Each factor shows AGMB's percentile within the scored universe — observational ranking, not a recommendation.
No sell-side coverage available for AGMB.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.